ALKS Alkermes Plc

ALKS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alkermes plc and a Lead Plaintiff Deadline of January 22, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Alkermes plc ("Alkermes") (NASDAQ: ALKS) securities between February 24, 2015 and November 3, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sb/alkermes-plc?wire=2. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Alkermes had engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol in addiction treatment programs over more scientifically proven and efficacious alternatives; (ii) the foregoing conduct, when disclosed, would subject Alkermes to heightened regulatory and legislative scrutiny; (iii) accordingly, the Company's revenues derived from Vivitrol during the Class Period were unsustainable; and (iv) as a result of the foregoing, Alkermes shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

If you suffered a loss in Alkermes you have until January 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/alkermes-plc?wire=2.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
20/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alkermes Plc

Alkermes, Inc.: Credit analysis following assignment of Ba2 CFR

Our credit view of this issuer reflects its strong credit metrics highlighted by moderate financial leverage, constrained by its pipeline execution and commercialization risk.

Moody's Ratings assigns Ba2 CFR to Alkermes; outlook stable

Moody's Ratings  (Moody's) assigned ratings to Alkermes, Inc. ("Alkermes"), including a Ba2 Corporate Family Rating (CFR), Ba2-PD Probability of Default Rating (PDR). Concurrently, we assigned Ba2 ratings to the senior secured bank credit facilities comprised of term loan A due 2031 and term loan B ...

Alkermes, Inc.: Update to credit analysis

Alkermes credit profile reflects its modest financial leverage and strong liquidity, offset by revenue concentration in three neuroscience-based products and approaching generic competition.

Moody's affirms Alkermes' Ba3 CFR, outlook stable

Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch